January 23, 2025) - Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, all ...
Sage Therapeutics has a unique approach to targeting GABA, which allows it to target CNS disorders. Read why I think SAGE ...
Applied Therapeutics was not adhering to trial protocol and good clinical practices which, in turn, created an exceedingly severe risk that the trial data would be rejected by the U.S. Food and Drug ...
Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...
Top-line Phase 2/3 data readout for CTX-009, now named tovecimig (a DLL4 x VEGF-A bispecific), in patients with biliary tract cancer (BTC) is on track for end of Q1 2025.CTX-10726 (a novel PD-1 x ...
Discover the potential of macrocycles in drug discovery: flexible, cell-permeable molecules targeting undruggable proteins.
Clinically significant reductions in bleeding underscore abelacimab’s strong potential to address an unmet need for patients ...
The development of the anti-migraine therapeutics, triptans-5-HT 1B/1D receptor agonists, had originally targeted the craniovasculature to exert therapeutic effects, and this locus of action ...
Dividend stocks can be a great way to boost your portfolio's growth potential or provide a form of passive income over the ...
PHILADELPHIA - Context Therapeutics Inc. (NASDAQ:CNTX), a company focused on developing treatments for solid tumors, announced the addition of Karen Smith, MD, PhD, MBA, LLM and... Context ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback